Breaking News
22 hours ago
Vaibhavi M.

FDA issues fourth supplemental approval for Takeda's HYQVIA, adding CIDP maintenance therapy to its labeled indications as of June 11, 2026.
Simantini Singh Deo

Roche's FDA approval of the first PTEN-loss companion diagnostic sets a new co-development and labeling benchmark for prostate cancer drug-diagnostic programmes.
Simantini Singh Deo

Lilly's Jaypirca cuts progression risk by 45% in Phase 3 CLL trial, signaling label expansion with manufacturing scale-up implications.
Simantini Singh Deo

Alithea Genomics and Revvity integrate MERCURIUS DRUG-seq into a global screening portfolio to scale transcriptomic profiling in early drug discovery.
Simantini Singh Deo
